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Abstract
The construction of the biologically interesting chromone skeleton was realized by PhIO-mediated dehydrogenation of chro-
manones under mild conditions. Interestingly, this method also found application in the synthesis of the naturally occurring fruti-
none A.
Introduction
The chromone system and its derivatives are an important class
of heterocyclic compounds, the skeleton of which widely exists
in a variety of natural products and medicinal agents [1-3]. It
was found that chromone derivatives exhibit a wide range of
pharmacological effects, including antibacterical [4], antifungal
[5,6], anticancer [7], antioxidant [8], anti-HIV [9], antiulcer,
immunostimulator [10], anti-inflammatory [11], as well as bio-
cidal [12], wound-healing [13], and immune-stimulatory activi-
ties [14]. For instance, flavoxate [15,16] is a chromone deriva-
tive that was employed as an anticholinergic agent for its
antimuscarinic effects [3,17]; apigenin can function as an
antiviral drug for the treatment of HIV [18,19], cancer [20-22],
and other viral infections [23]; pranlukast [24] can be used in
the treatment of allergic rhinitis [25] and asthma [26]; and
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khellin [27] has been proved to possess antiviral and antispas-
modic effects (Figure 1) [28]. All of these pharmaceutical
agents bear a chromone framework in their respective chemical
structure.
Figure 1: Biologically active chromone derivatives.
Since the chromone derivatives have a variety of biological ac-
tivities, developing synthetic methods for efficient construction
of the chromone skeleton has been a research field of great
interest and long history [2]. Among the numerous synthetic ap-
proaches [29-54], the dehydrogenative oxidation of the readily
available chromanones is a highly efficient method for the syn-
thesis of this privileged class of heterocycles. For example, Kim
and co-workers reported that chromones could be prepared via a
Pd(II)-catalyzed [55-57] dehydrogenation of chromanone deriv-
atives at 100 °C in DMSO (Scheme 1a) [58]. The synthesis of
chromones could also be realized by DDQ-mediated dehydro-
genation of chromanones under heating in dioxane (Scheme 1b)
[3,59,60]. In 2005, Yang and co-workers reported that
chromones could be formed by microwave irradiation of the
corresponding chromanone reactants and N-bromosuccinimide
(NBS) in the presence of a catalytic amount of azobis(iso-
butyronitrile) (AIBN) in CCl4 (Scheme 1c) [61,62]. In 2002,
Nicolaou and co-workers found that ortho-iodoxybenzoic acid
(IBX) could also effectively dehydrogenate chromanones to
chromones (Scheme 1d, method 1) [63]. Moreover, active
MnO2 was also found useful in the oxidative dehydrogenation
of chromanones at a relatively high temperature of 110 °C
(Scheme 1d, method 2) [64,65]. Although all of the above
methods have their respective merits in the preparation of the
corresponding chromone derivatives, it is obvious that some of
them suffer from drawbacks, such as the requirement of a high
reaction temperature, extended reaction time, involvement of
transition metal catalysts, and low yield. In these regards, the
development of alternative approaches that can realize an effi-
cient synthesis of chromones under mild conditions is desirable.
Scheme 1: Methods for the synthesis of chromones via dehydrogena-
tive oxidation of chromanones.
In recent decades, hypervalent iodine reagents have emerged as
a class of efficient and environmentally benign nonmetal
“green” oxidants [66-73]. For instance, iodosobenzene (PhIO)
[74] has been widely used in many synthetic transformations. It
was found that PhIO is efficient in realizing epoxidation of
olefins [75-77], converting alkynes and alkenes to ketones [78],
oxidizing alcohols to aldehydes [79,80], as well as in the direct
α-hydroxylation of ketones [81]. Furthermore, it could also be
used to realize oxidative C–C [82], C–N [83], and C–O [84]
bond formations. However, to the best of our knowledge, PhIO
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has never been utilized for the dehydrogenative oxidation reac-
tion. In this letter, we report a facile PhIO-mediated dehydroge-
nation of chromanones, resulting in the efficient synthesis of bi-
ologically interesting chromone compounds under metal-free
conditions.
Results and Discussion
We initially studied the feasibility of converting chromanone
ethyl 4-oxo-2-phenylchromane-3-carboxylate (1a) to chromone
2a via PhIO-mediated dehydrogenation. To our delight, when
1a was treated with PhIO in DCE at room temperature, the
desired product 2a could be obtained in 66% yield (Table 1,
entry 1), with the generation of some unidentified byproducts.
A solvent screening identified DMF to be the most appropriate
solvent for this transformation (Table 1, entries 1–9). Other
commonly employed oxidants, including phenyliodine(III)
diacetate (PIDA), phenyliodine(III) bis(trifluoroacetate) (PIFA),
and iodylbenzene (PhIO2), were found to be less efficient for
this transformation, as the desired product 2a was generated in
significantly lower yield in each case (Table 1, entries 10–12).
Further studies indicated that the reaction gave the best result if
performed at room temperature, while reduced or elevated tem-
perature (0 or 50 °C) was not beneficial for the reaction
(Table 1, entries 13 and 14). In addition, the amount of PhIO
was proved to be critical for this transformation, as a decreased
yield of the desired product, accompanied with more byprod-
ucts, was observed when increasing the PhIO amount from 2.0
to 3.0 mmol. When the amount of PhIO was reduced to
1.0 mmol, the yield also decreased due to the fact that the
starting material could not be completely consumed (Table 1,
entries 15 and 16). Based on the above screening results, the
optimal reaction conditions were concluded to be 1.0 mmol of
substrate, 2.0 mmol of PhIO, DMF as solvent, and 10 minutes
reaction time at room temperature.
With the optimized conditions in hand, we explored the scope
and generality of the newly established method. As shown in
Scheme 2, a wide range of chromanones could be well toler-
ated under the standard conditions, affording the expected prod-
ucts 2a–x in satisfactory to good yields. Substrates bearing
various R1 substituents (F, Cl, Br, CN, NO2, Me, OMe) were all
efficiently converted to the corresponding products 2a–i, with
the substrates carrying electron-donating groups affording the
desired products 2h and 2i in noticeably higher yields than
those with electron-withdrawing groups, 2b–g. The product 2g,
with an electron-withdrawing group in ortho position, was
formed in a much lower yield, most likely due to steric
hindrance. When the phenyl group was replaced by a naphthyl
group, less of the corresponding substrate was converted to the
desired product 2j. The substrates bearing various R2 substitu-
ents, including electron-withdrawing, electron-donating, steri-
Table 1: Optimization of reaction conditions.a
entry oxidant solvent T (°C) yield
(%)b
1 PhIO DCE rt 66
2 PhIO THF rt 57
3 PhIO toluene rt 42
4 PhIO 1,4-dioxane rt 33
5 PhIO DMSO rt 53
6 PhIO DMF rt 89
7 PhIO MeOH rt 33
8 PhIO MeCN rt 37
9 PhIO EtOAc rt 35
10 PIDA DMF rt 62
11 PIFA DMF rt 21
12 PhIO2 DMF rt 46
13 PhIO DMF 0 38
14 PhIO DMF 50 65
15c PhIO DMF rt 64
16d PhIO DMF rt 78
aReaction conditions: 1a (1.0 mmol), oxidant (2.0 mmol), solvent
(6 mL). bIsolated yield. c1a (1.0 mmol), PhIO (1.0 mmol), DMF (6 mL).
d1a (1.0 mmol), PhIO (3.0 mmol), DMF (6 mL), 10 min.
cally hindered, and heterocyclic groups, all reacted smoothly
and afforded the desired chromone derivatives 2k–v in accept-
able to good yields. Furthermore, when the ethoxycarbonyl
group R3 was replaced by an acetyl substituent, the resulting
substrate was successfully converted to 2w with a high yield.
However, when the substrate bore a strong electron-with-
drawing cyano group, the reaction was less efficient. and the
product 2x was produced in a much lower yield. When the elec-
tron-withdrawing group (R3) in substrate 1 was replaced by
hydrogen, the corresponding product 2y was obtained in a rela-
tively low yield. To our disappointment, the method was not
applicable to the synthesis of 4-chromones, as the reaction of
4-chromanones did not occur under the standard conditions
(2z). But when R3 was a carbonyl group and R2 was a hydro-
gen atom, the corresponding compound 1aa could also be con-
verted to the desired product with 35% yield. On the basis of
these results, we tentatively proposed that the failure of 1z for-
mation might have been caused by the absence of a carbonyl
group in its chemical structure [85].
Control experiments were designed and conducted to elucidate
the reaction mechanism of this transformation. When 3 equiv of
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Scheme 2: Substrate scope studies. Reaction conditions: 1 (1.0 mmol), PhIO (2.0 mmol), DMF (6 mL), rt. Isolated yields are given.
TEMPO, a radical-trapping reagent, were added to the reaction
mixture, product 2a was obtained in 55% yield (Scheme 3,
method a). When another radical-trapping reagent, BHT, was
used, the reaction gave 50% yield of the desired product 2a
(Scheme 3, method b). Since the reaction was not greatly
suppressed in both cases, we tentatively propose that this dehy-
drogenative oxidation reaction may undergo both radical and
nonradical pathways.
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Scheme 4: Proposed reaction mechanism.
Scheme 3: Control experiments for mechanistic studies.
Based on previous reports [63,86] and our own experimental
results, two plausible mechanisms for this dehydrogenation
reaction are proposed (Scheme 4): In pathway a, substrate 1a is
first tautomerized to its enol form A, which would be stabilized
by an internal H-bond. It is highly likely that the enolization is a
necessary process for the reaction to occur, as compound 2z
could not undergo the transformation under the standard condi-
tions. Then, nucleophilic attack on the iodine center of PhIO
[87] by the enol moiety of intermediate A affords the O–I enol
form C (via intermediate B), which is subsequently converted
to I–C intermediate D via radical migration [88]. The homoge-
neous cleavage of the C–I bond in D leads to the stable carbon
radical E and an iodine radical. Finally, the reaction between E
and the iodine radical produces product 2a, with the concomi-
tant release of water and iodobenzene. In pathway b, the O–I
intermediate C is converted to a C–I intermediate D via 1,3-
migration [89]. Then, intermediate D carries through a five-
membered ring transition state F to afford the title product 2a,
accompanied by the release of iodobenzene and water.
One practical application of the obtained chromone derivatives
was their conversion to chromone-derived natural products.
Frutinone A, isolated from the leaves and root bark of Polygala
fruticosa, shows various biological activities, including antibac-
terial, antioxidant, and potent cytochrome P450 1A2 inhibition
(CYP1A2, IC50 = 5.3 nM) properties [90-92]. Treating the ob-
tained chromene-3-carboxylate 2l with LiOH [93] led to the for-
mation of the chromene-3-carboxylic acid G. Heating com-
pound G overnight in the presence of AgNO3 and K2S2O8
afforded frutinone A in an isolated yield of 45% (Scheme 5).
Scheme 5: Application of the reported method to the synthesis of fruti-
none A.
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Conclusion
In summary, we have developed an efficient metal-free ap-
proach for the synthesis of chromone derivatives via PhIO-
mediated dehydrogenative oxidation of chromanones. Com-
pared with the existing methods, the new reaction features mild
conditions, high efficiency, and is metal-free. Moreover, the
product 2l could be further applied to the synthesis of the natu-
rally occurring frutinone A.
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